Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 13;32(11):1897-1909.e7.
doi: 10.1016/j.chom.2024.09.014. Epub 2024 Oct 17.

Vaginal lactobacilli produce anti-inflammatory β-carboline compounds

Affiliations

Vaginal lactobacilli produce anti-inflammatory β-carboline compounds

Virginia J Glick et al. Cell Host Microbe. .

Abstract

The optimal vaginal microbiome is a Lactobacillus-dominant community. Apart from Lactobacillus iners, the presence of Lactobacillus species is associated with reduced vaginal inflammation and reduced levels of pro-inflammatory cytokines. Loss of Lactobacillus-dominance is associated with inflammatory conditions, such as bacterial vaginosis (BV). We have identified that Lactobacillus crispatus, a key vaginal bacterial species, produces a family of β-carboline compounds with anti-inflammatory activity. These compounds suppress nuclear factor κB (NF-κB) and interferon (IFN) signaling downstream of multiple pattern recognition receptors in primary human cells and significantly dampen type I IFN receptor (IFNAR) activation in monocytes. Topical application of an anti-inflammatory β-carboline compound, perlolyrine, was sufficient to significantly reduce vaginal inflammation in a mouse model of genital herpes infection. These compounds are enriched in cervicovaginal lavage (CVL) of healthy people compared with people with BV. This study identifies a family of compounds by which vaginal lactobacilli mediate host immune homeostasis and highlights a potential therapeutic avenue for vaginal inflammation.

Keywords: Lactobacillus; bacterial vaginosis; beta-carbolines; genital herpes; inflammation; perlolyrine; vaginal microbiome; vaginal mucosa.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests C.W., M.C.M., S.B., J.C., K.H.K., and S.G. are co-inventors on a patent related to this work.

References

    1. Skelly AN, Sato Y, Kearney S, and Honda K (2019). Mining the microbiota for microbial and metabolite-based immunotherapies. Nat. Rev. Immunol 19, 305–323. 10.1038/s41577-019-0144-5. - DOI - PubMed
    1. France M, Alizadeh M, Brown S, Ma B, and Ravel J (2022). Towards a deeper understanding of the vaginal microbiota. Nat. Microbiol 7, 367–378. 10.1038/s41564-022-01083-2. - DOI - PMC - PubMed
    1. Armstrong E, and Kaul R (2021). Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk. Microbiome 9, 239. 10.1186/s40168-021-01183-x. - DOI - PMC - PubMed
    1. Gosmann C, Anahtar MN, Handley SA, Farcasanu M, Abu-Ali G, Bowman BA, Padavattan N, Desai C, Droit L, Moodley A, et al. (2017). Lactobacillus -deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity 46, 29–37. 10.1016/j.immuni.2016.12.013. - DOI - PMC - PubMed
    1. Fettweis JM, Serrano MG, Brooks JP, Edwards DJ, Girerd PH, Parikh HI, Huang B, Arodz TJ, Edupuganti L, Glascock AL, et al. (2019). The vaginal microbiome and preterm birth. Nat. Med 25, 1012–1021. 10.1038/s41591-019-0450-2. - DOI - PMC - PubMed

LinkOut - more resources